Product logins

Find logins to all Clarivate products below.


Interventional Oncology Devices | Market Insights | Europe | 2022

While the COVID-19 pandemic will have a negative, albeit relatively limited, impact on European interventional oncology device market in the short term, the market will grow moderately over the forecast period, driven by an expanding patient population, improved reimbursement leading to adoption of premium-priced devices, and increased physician training on interventional oncology procedures. However, revenue growth will be limited to some extent due to increasing price competition and ongoing cost constraints in the region.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in Europe across a 11-year period.

Related Medtech Insights Reports

Report
Interventional Cardiology Devices – Market Insights – Europe
The European interventional cardiology device market is highly competitive and poised for moderate growth over the forecast period, driven by increasing PCI volumes for complex CAD cases and the…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Europe
The European EP mapping and ablation device market will grow moderately through 2035, driven by the rising prevalence of cardiac arrhythmias, improved access to treatment, advancements in ablation…
Report
Aortic Repair Devices – Market Insights – Europe
The European aortic stent graft market is the primary driver of growth in the aortic repair device market and will drive revenue expansion over the forecast period, supported by ongoing innovation…
Report
Cardiac Rhythm Management Devices – Market Insights – Europe
The European CRM device market will continue to grow modestly over the forecast period because of rising ICM procedure volumes, the introduction of dual-chamber leadless pacemakers, and increased…
Report
Gastrointestinal Endoscopy Devices – Market Insights – Europe
The European GI endoscopy device market will be driven primarily by the high incidence of gastric cancer and CRC in the region. Market growth will be supported by nationwide CRC and GI cancer…